Description

FOXO4-DRI 10mg (Proxofim) – Senolytic Research Peptide

FOXO4-DRI 10mg, sometimes referred to commercially as Proxofim, is an experimental research peptide associated with investigations into cellular senescence, FOXO4-p53 protein interactions and apoptosis signalling. FOXO4-DRI belongs to a class of synthetic peptides designed using D-retro-inverso technology.

The peptide has attracted scientific interest because preclinical studies have investigated whether disruption of the FOXO4-p53 interaction can influence the survival of senescent cells. These cells can accumulate following cellular stress and may contribute to age-associated changes in tissue function.

In a landmark 2017 study, researchers reported that FOXO4-DRI promoted apoptosis in selected senescent cell models and improved certain tissue-related outcomes in mice. However, these results remain preclinical and do not establish anti-ageing benefits or safety in humans.

This FOXO4-DRI 10mg product description explores the peptide’s molecular design, proposed mechanism, scientific research applications, experimental limitations and important laboratory quality considerations.

What Is FOXO4-DRI Peptide?

FOXO4-DRI is a synthetic peptide designed to interfere with the interaction between the FOXO4 transcription factor and the tumour suppressor protein p53.

FOXO4 belongs to the forkhead box O family of transcription factors, which participate in the regulation of cellular stress responses, gene expression and other biological processes.

Research has identified interactions between FOXO4 and p53 as potentially relevant to the survival of certain senescent cells.

FOXO4-DRI was developed as an experimental tool to investigate whether disrupting this interaction could alter cell survival.

The name DRI refers to D-retro-inverso peptide design, in which amino acid chirality and sequence direction are modified to reproduce aspects of a parent peptide’s molecular presentation.

FOXO4-DRI is not the naturally occurring FOXO4 protein and is not an established medicine for ageing-related conditions.

FOXO4-DRI 10mg Product Specifications

• Product Name: FOXO4-DRI 10mg
• Alternative Name: FOXO4 D-Retro-Inverso Peptide
• Commercial Research Name: Proxofim
• Additional Name: FOXO4-p53 Interfering Peptide
• Classification: Synthetic D-retro-inverso research peptide
• Reference Peptide Length: 46 amino acid residues
• Reference Molecular Formula: C228H388N86O64
• Approximate Molecular Weight: 5,358.2 g/mol
• Reference Sequence: H-ltlrkepaseiaqsileaysqngwanrrsggkrppprrrqrrkkrg-OH
• Sequence Convention: Lowercase letters denote D-amino-acid residues
• Labelled Quantity: 10mg
• Research Target: FOXO4-p53 protein interaction
• Research Category: Cellular senescence and experimental senolytic research
• Research Focus: Senescent cell survival, apoptosis and cellular stress responses
• Purity: Requires batch-specific verification
• Salt Form: Confirm with manufacturer
• Physical Form: Confirm with manufacturer
• Storage: Follow verified manufacturer instructions
• Intended Use: Laboratory research

The molecular specifications above describe the FOXO4-DRI reference construct reported in the scientific literature. Commercially supplied variants, counterions and salt forms may differ. The identity of material marketed as Proxofim should be confirmed against the actual supplier documentation.

Understanding the Molecular Structure of FOXO4-DRI

FOXO4-DRI uses a D-retro-inverso molecular design.

In this approach, the sequence of a parent peptide is reversed and D-amino-acid residues are used in place of the corresponding L-amino-acid residues.

This strategy aims to preserve certain spatial relationships between amino acid side chains while changing the orientation of the peptide backbone.

D-retro-inverso peptides may show increased resistance to some proteolytic enzymes under experimental conditions.

However, increased protease resistance does not establish a specific half-life or safety profile in humans.

The original FOXO4-DRI research construct also includes a cell-penetrating sequence designed to support intracellular access.

Researchers should verify the complete sequence, stereochemistry and any attached functional domains because these features are essential to molecular identity.

How Does FOXO4-DRI Work?

FOXO4-DRI was designed to interfere with the interaction between FOXO4 and p53.

FOXO4 is a transcription factor involved in cellular responses to stress, while p53 participates in DNA damage responses, cell-cycle regulation and apoptosis.

Some senescent cells display altered survival mechanisms that allow them to persist despite significant cellular damage.

Experimental research suggests that FOXO4 can contribute to the survival of certain senescent cells through interactions involving p53.

By disrupting this interaction, FOXO4-DRI has been reported to promote p53-associated apoptotic signalling in selected preclinical models.

However, this mechanism has not been demonstrated to produce safe, selective or beneficial senescent-cell elimination in humans.

Scientific Research Into FOXO4-DRI

1. Cellular Senescence Research

Cellular senescence is a state in which cells undergo a persistent reduction or arrest of normal cell-cycle progression.

Senescence can arise in response to telomere dysfunction, DNA damage, oncogene activation and other forms of cellular stress.

Senescent cells may contribute to tissue dysfunction when they accumulate in certain biological environments.

However, cellular senescence also has important protective functions, including limiting the proliferation of damaged cells.

FOXO4-DRI has been investigated as an experimental tool for studying the survival of selected senescent cell populations.

These investigations contribute to understanding the complex relationship between senescence, tissue maintenance and ageing biology.

2. FOXO4 and p53 Interaction Research

FOXO4 and p53 are proteins involved in cellular stress responses.

Researchers have investigated whether their interaction influences the survival of cells that have entered senescence.

In the original FOXO4-DRI research, disrupting this interaction was associated with changes in p53 localisation and apoptosis-related responses.

These findings suggest that the FOXO4-p53 interaction may represent an experimental target in senescence biology.

However, p53 participates in many essential biological processes, including tumour suppression.

Manipulating p53-associated pathways requires careful investigation of potential effects outside the intended experimental cell population.

3. Senescent Cell Apoptosis Research

Apoptosis is a regulated process of programmed cell death.

It contributes to normal development, tissue maintenance and the removal of certain damaged cells.

Some senescent cells exhibit altered sensitivity to apoptosis.

FOXO4-DRI has been investigated for its ability to influence apoptosis in selected senescent cell models.

The 2017 study reported preferential effects on senescent cells under specific experimental conditions.

However, these results do not establish that FOXO4-DRI can safely remove all harmful senescent cells without affecting healthy tissues.

4. Senolytic Research

Senolytics are experimental compounds investigated for their ability to eliminate certain senescent cells.

FOXO4-DRI is often described as a senolytic research peptide because of its reported effects in preclinical senescence models.

Senolytic research aims to understand whether selective removal of particular senescent cell populations can influence tissue function.

Different senolytic compounds act through different molecular mechanisms.

FOXO4-DRI is associated with interference in the FOXO4-p53 interaction rather than direct inhibition of every pathway involved in cellular senescence.

Clinical effectiveness and safety remain unestablished.

5. Ageing Biology Research

Ageing is a complex biological process involving multiple molecular and cellular changes.

These include genomic instability, altered cellular signalling, mitochondrial dysfunction and changes in tissue repair.

Senescent cell accumulation is one of several processes investigated in ageing research.

FOXO4-DRI attracted attention after animal studies reported improvements in selected physiological measurements.

However, improved measurements in mice do not demonstrate reversal of human ageing.

There is no reliable clinical evidence that FOXO4-DRI extends human lifespan or improves healthspan.

6. Chemotherapy-Induced Senescence Research

Some cancer treatments can produce senescence-related changes in exposed cells and tissues.

Experimental research has investigated whether senescent cell accumulation contributes to certain tissue effects following chemotherapy.

The original FOXO4-DRI study included mouse models involving the chemotherapeutic agent doxorubicin.

Researchers reported changes in selected tissue-related outcomes following experimental intervention.

These findings do not establish FOXO4-DRI as a treatment for chemotherapy side effects or cancer-related complications in humans.

7. Kidney and Tissue Homeostasis Research

Tissue homeostasis refers to the maintenance of relatively stable biological conditions within tissues.

Ageing and cellular stress can alter this balance.

Preclinical FOXO4-DRI research included measurements related to kidney function and tissue responses in mice.

Some experimental results suggested improvements in selected renal-associated markers.

However, these findings were obtained in animal models and cannot establish kidney protection or improved renal function in humans.

8. Cell-Penetrating Peptide Research

Cell-penetrating peptides are designed to facilitate interactions with cellular membranes and intracellular environments.

The original FOXO4-DRI construct incorporates a cell-penetrating segment.

This structural feature is relevant because FOXO4 and p53 interact inside cells rather than at the cell surface.

Researchers investigate how cell-penetrating sequences influence intracellular access and experimental activity.

However, the presence of such a sequence does not guarantee uniform delivery, tissue selectivity or safety in living organisms.

9. D-Retro-Inverso Peptide Design Research

D-retro-inverso technology is an approach used in peptide engineering.

It combines reversal of amino acid sequence direction with inversion of amino acid chirality.

The resulting peptide can reproduce certain side-chain arrangements of the parent molecule while exhibiting different backbone properties.

Researchers investigate these designs for their effects on molecular stability and protein interactions.

FOXO4-DRI is an example of how D-retro-inverso technology has been applied to experimental protein-protein interaction research.

FOXO4-DRI vs FOXO4: What Is the Difference?

FOXO4 and FOXO4-DRI are not the same molecule.

• FOXO4: A naturally occurring human transcription factor involved in cellular stress responses and gene regulation.
• FOXO4-DRI: A synthetic research peptide designed to interfere with a specific FOXO4-associated protein interaction.
• Molecular Structure: FOXO4 is a much larger protein, while FOXO4-DRI is a modified peptide construct.
• Research Role: FOXO4 is studied as a biological regulator, while FOXO4-DRI is investigated as an experimental intervention.

Research findings involving the FOXO4 protein cannot automatically be attributed to FOXO4-DRI.

FOXO4-DRI vs Other Senolytic Research Compounds

FOXO4-DRI is one of several experimental approaches investigated in senescence research.

Other compounds have been studied for their effects on pathways involved in senescent cell survival.

For example, dasatinib and quercetin have been investigated in selected experimental senolytic research programmes.

However, these compounds differ substantially in their molecular structures and biological targets.

FOXO4-DRI specifically attracted attention for its proposed interference with the FOXO4-p53 interaction.

Evidence involving one senolytic compound should not be assumed to establish the effectiveness or safety of another.

FOXO4-DRI and Anti-Ageing Research

FOXO4-DRI is frequently discussed in anti-ageing research because of its reported effects on senescent cells in preclinical studies.

However, cellular senescence is only one component of ageing biology.

Eliminating certain senescent cells in mice does not demonstrate that an intervention reverses ageing in humans.

There are no established human clinical trials demonstrating that FOXO4-DRI extends lifespan, restores youthful tissue function or prevents age-related disease.

Claims of proven rejuvenation or age reversal are therefore unsupported.

FOXO4-DRI and Weight Management

FOXO4-DRI is not an established weight-loss peptide.

Its principal research focus involves cellular senescence, FOXO4-p53 signalling and experimental apoptosis.

There is insufficient clinical evidence that FOXO4-DRI reduces body fat, suppresses appetite or treats obesity.

It should not be described as a proven fat-burning or metabolic weight-management treatment.

Understanding the FOXO4-DRI 10mg Label

The 10mg designation refers to the labelled quantity of research material.

It does not represent a recommended human dose or independently establish the identity, purity, sterility or biological activity of the supplied peptide.

Researchers should verify the complete sequence, D-amino-acid configuration, salt form and batch-specific analytical documentation.

FOXO4-DRI 10mg Research Quality and Product Documentation

Important considerations when evaluating FOXO4-DRI research material include:

• Verification of the complete peptide sequence
• Confirmation of the D-retro-inverso configuration
• Verification of the cell-penetrating segment
• Identification of the supplied salt form
• Batch-specific certificate of analysis
• Appropriate analytical purity testing
• Mass spectrometry or another suitable identity method
• Accurate labelled peptide quantity
• Assessment of synthesis-related impurities
• Manufacturer and batch traceability
• Documentation of counterions and formulation components
• Verified packaging specifications
• Product-specific storage and stability documentation
• Clearly stated research-use classification

These records help distinguish chemically characterised research material from products identified only by commercial naming conventions.

Storage and Handling of FOXO4-DRI

FOXO4-DRI research material should be stored according to verified manufacturer instructions.

Storage requirements depend on the supplied molecular form, formulation, packaging and stability characteristics.

Researchers should not assume that all FOXO4-DRI products have identical storage conditions or shelf-life characteristics.

Laboratory handling should follow relevant safety documentation and institutional procedures.

FOXO4-DRI Safety and Scientific Limitations

FOXO4-DRI remains an experimental peptide with no established human clinical safety profile.

Published evidence primarily involves laboratory experiments and animal models.

Potential concerns include effects on non-target cells, interference with important p53-associated biological processes, immune reactions, peptide-related impurities and unknown long-term consequences.

Senescent cells can also perform protective biological functions, so their removal should not automatically be assumed beneficial.

FOXO4-DRI is not an established FDA-, EMA- or MHRA-approved medicine for ageing, cancer, weight management or other medical conditions.

Research-grade material must not be assumed suitable for injection, ingestion or other human administration.

This information is intended for scientific and educational purposes only and does not provide medical advice, human dosing recommendations or administration instructions.

Frequently Asked Questions About FOXO4-DRI 10mg

What is FOXO4-DRI 10mg?

FOXO4-DRI 10mg is a product listing for an experimental D-retro-inverso research peptide with a labelled quantity of 10mg.

What does FOXO4-DRI stand for?

FOXO4 refers to Forkhead Box O4, while DRI refers to D-retro-inverso peptide design.

What is Proxofim?

Proxofim is a name associated with FOXO4-DRI in commercial research listings. The exact molecular identity of a product carrying this name should be verified.

How many amino acids are in FOXO4-DRI?

The original published research construct contains 46 amino acid residues.

What is the molecular weight of FOXO4-DRI?

The original reference construct has an approximate molecular weight of 5,358.2 g/mol.

What is FOXO4-DRI researched for?

FOXO4-DRI is investigated in cellular senescence, apoptosis, FOXO4-p53 interaction and experimental senolytic research.

Does FOXO4-DRI eliminate senescent cells?

Selected laboratory and animal studies have reported apoptosis in certain senescent cell populations. Safe and effective senescent-cell elimination in humans has not been established.

Does FOXO4-DRI reverse ageing?

No reliable human clinical evidence demonstrates that FOXO4-DRI reverses ageing or extends lifespan.

Is FOXO4-DRI a weight-loss peptide?

No. FOXO4-DRI is not an established treatment for obesity or weight management.

Is FOXO4-DRI approved for medical use?

No. FOXO4-DRI is not an established approved medicine for human therapeutic use.

What does FOXO4-DRI 10mg mean?

The 10mg designation refers to the labelled quantity of research material, not a recommended human dose.

FOXO4-DRI 10mg – Product Summary

FOXO4-DRI 10mg is a synthetic D-retro-inverso peptide associated with scientific investigations into cellular senescence, FOXO4-p53 protein interactions and apoptosis signalling.

Its molecular design and experimental activity have made it an important subject in preclinical senolytic research.

However, there is no established human clinical evidence demonstrating that FOXO4-DRI safely reverses ageing, improves longevity or treats age-related disease.

Researchers should verify the exact peptide sequence, stereochemistry, salt form, purity, batch documentation and storage requirements before selecting FOXO4-DRI 10mg for laboratory investigation.